Humacyte, Inc. Common Stock

Day range

$0.39 – $0.46

Open

$0.46

Prev close

$0.44

Volume

3.97M

Market cap

$120.95M

Shares out

277.8M

P/E

—

P/S

57.63

P/B

3.91

P/FCF

—

ROE

-309.4%

ROA

-70.0%

Debt/Equity

2.12

Div yield

0.00%

As of Oct 23, 2026

• Executive compensation changeSep 28, 2026

  For their service on the Board, each of Mr. Coward and Mr. Kuznik will participate in the Company's previously disclosed compensation program for non-employee directors, pursuant to which each will receive (i) a $50,000 annual cash retainer... (ii) $5,000 per annum for service on a board committee... and (iii) an option to purchase 125,000 shares of the Company's common stock.

• Listing deficiency noticeJul 31, 2026

  On July 31, 2026, Humacyte, Inc. (the "Company") received a letter from the staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") providing notification that, for the 30 consecutive business days ended July 30, 2026, the bid price for the Company's common stock, par value $0.0001 per share (the "Common Stock"), had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until January 27, 2027, to regain compliance.

• Underwriting agreementJun 11, 2026

  On June 10, 2026, Humacyte, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the issuance and sale in an underwritten offering (the "Offering"). The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended (the "Securities Act"), and termination provisions.

• Clinical trial resultsJun 10, 2026

  On June 10, 2026, Humacyte, Inc. (the "Company") issued a press release announcing the presentation of results from its Phase 3 clinical trial (V012) of the acellular tissue engineered vessel (ATEV) in arteriovenous access for female patients with end-stage renal disease requiring hemodialysis.

• Charter amendmentJun 9, 2026

  the Company's stockholders approved an amendment to the Company's Second Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") to increase the number of authorized shares of the Company's common stock from 350,000,000 to 550,000,000 (the "Amendment"). The Amendment became effective upon the filing thereof with the Secretary of State of the State of Delaware on June 9, 2026.

Days to cover

7.3

Short interest

29.4M

Avg volume

4.02M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today
  negativeZacks Investment Research· Oct 21, 2026
• Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
  negativeZacks Investment Research· Oct 19, 2026
• Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
  negativeZacks Investment Research· Oct 13, 2026
• Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade
  negativeZacks Investment Research· Oct 6, 2026
• Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
  negativeZacks Investment Research· Oct 1, 2026